California Seeks Advisers on Marijuana Rules
The Bureau of Medical Cannabis Regulation is now accepting applications for a marijuana advisory committee to help inform the agency as the state sets up rules governing the new industry.
Medical cannabis laws passed by the Legislature in 2015 and the recreational legalization measure voters approved in November established similar overarching regulatory frameworks related to cultivation, manufacturing, transportation, sales and other aspects of the marijuana market. State agencies are tasked with developing specific rules to best implement the new laws.
The state intends to create a singular regulatory system for both medical and recreational marijuana by the end of the year. Some question the feasibility of establishing a model for a multi-billion dollar industry in such a short time frame.
Read more at The Sacramento Bee.
The Next Big Brain Cancer Drug Could Come from Marijuana
GW Pharmaceuticals (NASDAQ: GWPH) is already well on its way to winning the first-ever U.S. approval for a cannabis-derived therapy. But an early trial suggests that these treatments could also be an effective way to fight one of most devastating forms of brain cancers: glioblastoma multiforme.
The U.K.-based company unveiled preliminary data Tuesday from a mid-stage study on an experimental drug combining cannabidiol and THC, the “high” producing element of marijuana. Results so far show that the drug boosted brain cancer patients’ median survival rates by about six months compared to a placebo. Typically, this type of cancer ravages the brain and (on average) leaves 70% of patients dead within two years of being diagnosed.
“We believe that the signals of efficacy demonstrated in this study further reinforce the potential role of cannabinoids in the field of oncology and provide GW with the prospect of a new and distinct cannabinoid product candidate in the treatment of glioma,” GW CEO Justin Gover said in a statement.
Read more at Fortune.
Volunteers Needed for Clinical Trial of Marijuana for PTSD Symptoms
Researchers started this week the first-ever clinical trial of marijuana for treating the effects of post-traumatic stress disorder in veterans.
The trial will test four potencies of smoked marijuana and their effects to manage PTSD symptoms in 76 veterans, according to the Multidisciplinary Association for Psychedelic Studies. Approved by the Drug Enforcement Administration and the Food and Drug Administration, the study is intended to develop marijuana into a legal prescription drug.
“We are thrilled to see this study overcome the hurdles of approval so we can begin gathering the data,” Amy Emerson said in a written statement issued by the association. The nonprofit drives clinical research on the medicinal use of marijuana, LSD and MDMA, known more broadly as Ecstasy.
“This study is a critical step in moving our botanical drug development program forward at the federal level to gather information on the dosing, risks and benefits of smoked marijuana for PTSD symptoms.”
The $2.2 million trial is funded by the Colorado Department of Public Health and Environment. The first participant received marijuana Monday.
Read more at Military.com.
Latest posts by Paul Ebeling (see all)
- Key Stock Indexes, Crude, Gold & Silver Markets Briefing - February 21, 2017
- Commentary: Paul Ebeling on Wall Street - February 21, 2017
- Wall Street’s Top Analysts Upgrades, Downgrades & Initiations - February 21, 2017